ISRIB

• Dry-fill capsules (25 mg per capsule, 60-count / 1.5 g total)
• 5 grams powder

Research indicates ISRIB acts by targeting translational-control mechanisms within the ISR pathway: This mechanism differentiates ISRIB from anxiolytics or stimulants, as it operates at the level of cellular resilience and translational efficiency rather than neurotransmitter release.

• Binds to and stabilizes eIF2B, the guanine-nucleotide exchange factor for eIF2
• Restores protein synthesis suppressed by ISR activation
• Counteracts the effects of eIF2α phosphorylation without blocking stress sensing
• Enhances synaptic-protein translation required for learning and memory
• Supports cellular recovery following metabolic or proteotoxic stress

ISRIB is commonly studied in

• Learning and memory-consolidation models
• Cognitive recovery after stress or injury
• Neuroplasticity and synaptic-remodeling research
• Traumatic-brain-injury models
• Neurodegenerative-disease pathways
• Cellular stress-adaptation studies
• Age-related cognitive-decline models

Reported or historically noted findings include: Because ISRIB modifies a core cellular stress-response pathway, it is typically studied with caution and in tightly controlled experimental settings.

• Minimal acute behavioral side effects in preclinical studies
• Potential for excessive protein synthesis if misapplied in non-stress contexts
• Limited long-term safety data in chronic-use models
• No classic stimulant or sedative profile observed

Researchers typically avoid combining ISRIB with agents that heavily suppress stress signaling upstream, as ISRIB’s effects rely on intact stress detection with restored translation.